Pictet Asset Management Holding SA Has $239,000 Stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Pictet Asset Management Holding SA raised its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 58.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 35,397 shares of the company’s stock after purchasing an additional 13,066 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Recursion Pharmaceuticals were worth $239,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the business. Farther Finance Advisors LLC raised its holdings in shares of Recursion Pharmaceuticals by 21.1% in the fourth quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company’s stock valued at $52,000 after buying an additional 1,353 shares during the last quarter. Wedmont Private Capital raised its stake in shares of Recursion Pharmaceuticals by 10.6% in the fourth quarter. Wedmont Private Capital now owns 20,943 shares of the company’s stock worth $144,000 after acquiring an additional 2,000 shares during the last quarter. Daiwa Securities Group Inc. lifted its position in shares of Recursion Pharmaceuticals by 28.3% during the fourth quarter. Daiwa Securities Group Inc. now owns 10,135 shares of the company’s stock worth $69,000 after purchasing an additional 2,235 shares in the last quarter. Green Alpha Advisors LLC grew its stake in shares of Recursion Pharmaceuticals by 3.6% during the fourth quarter. Green Alpha Advisors LLC now owns 67,145 shares of the company’s stock valued at $454,000 after purchasing an additional 2,346 shares during the last quarter. Finally, Xponance Inc. increased its holdings in shares of Recursion Pharmaceuticals by 22.2% in the fourth quarter. Xponance Inc. now owns 19,163 shares of the company’s stock valued at $130,000 after purchasing an additional 3,480 shares in the last quarter. Institutional investors own 89.06% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Leerink Partners reduced their price objective on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating on the stock in a report on Friday, February 28th. Needham & Company LLC reiterated a “buy” rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a report on Tuesday. Morgan Stanley dropped their price objective on Recursion Pharmaceuticals from $10.00 to $8.00 and set an “equal weight” rating for the company in a report on Thursday. Cowen reaffirmed a “hold” rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Finally, KeyCorp dropped their price target on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $8.20.

Recursion Pharmaceuticals Price Performance

Shares of RXRX opened at $4.51 on Friday. The stock has a market cap of $1.81 billion, a P/E ratio of -2.95 and a beta of 1.00. Recursion Pharmaceuticals, Inc. has a 1 year low of $3.79 and a 1 year high of $12.36. The stock’s 50-day moving average price is $6.87 and its two-hundred day moving average price is $6.84. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings data on Friday, February 28th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.17). The firm had revenue of $4.60 million for the quarter, compared to analyst estimates of $19.04 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm’s revenue for the quarter was down 57.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.42) EPS. On average, equities analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.